- Home
- NEOV vs FENC Comparison
NEOV vs FENC Comparison
Compare NEOV & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEOV
- FENC
- Stock Information
- Founded
- NEOV 2018
- FENC 1996
- Country
- NEOV United States
- FENC United States
- Employees
- NEOV N/A
- FENC N/A
- Industry
- NEOV Industrial Machinery/Components
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NEOV Miscellaneous
- FENC Health Care
- Exchange
- NEOV Nasdaq
- FENC Nasdaq
- Market Cap
- NEOV 153.9M
- FENC 225.4M
- IPO Year
- NEOV N/A
- FENC 2001
- Fundamental
- Price
- NEOV $5.03
- FENC $8.85
- Analyst Decision
- NEOV Strong Buy
- FENC Strong Buy
- Analyst Count
- NEOV 1
- FENC 2
- Target Price
- NEOV $7.50
- FENC $13.50
- AVG Volume (30 Days)
- NEOV 240.4K
- FENC 56.2K
- Earning Date
- NEOV 11-07-2025
- FENC 11-06-2025
- Dividend Yield
- NEOV N/A
- FENC N/A
- EPS Growth
- NEOV N/A
- FENC N/A
- EPS
- NEOV N/A
- FENC N/A
- Revenue
- NEOV $4,255,136.00
- FENC $33,302,000.00
- Revenue This Year
- NEOV $208.50
- FENC $0.96
- Revenue Next Year
- NEOV $128.75
- FENC $51.71
- P/E Ratio
- NEOV N/A
- FENC N/A
- Revenue Growth
- NEOV 52.64
- FENC N/A
- 52 Week Low
- NEOV $1.80
- FENC $3.96
- 52 Week High
- NEOV $6.11
- FENC $9.42
- Technical
- Relative Strength Index (RSI)
- NEOV 64.60
- FENC 52.15
- Support Level
- NEOV $3.40
- FENC $8.96
- Resistance Level
- NEOV $5.41
- FENC $9.13
- Average True Range (ATR)
- NEOV 0.35
- FENC 0.32
- MACD
- NEOV 0.19
- FENC -0.03
- Stochastic Oscillator
- NEOV 81.10
- FENC 49.71
About NEOV NeoVolta Inc.
NeoVolta Inc is engaged in designing, manufacturing and sale of high end Energy Storage System which can store and use solar energy via batteries and an inverter at a residential site. Its market place includes solar industry, installers, new construction homebuilders, home remodelers and homeowners.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.